Prior to joining MPM, Steve was Senior Director of Business Development for Eli Lilly and Company. In that role, he focused on Lilly’s limited partnerships in top-tier venture funds, direct equity investments and other “shared-risk” relationships with biotech companies. Prior to Lilly, Steve co-led the Bioscience Ventures group within 2M Companies, the Dallas-based family office of Morton H. Meyerson, focusing on early-stage private healthcare investments. Before 2M, he worked at Reata Pharmaceuticals, running the Technology Evaluation and In-Licensing program, where he led the in-licensing of an asset that is now in clinical development.
As a volunteer, Steve sits on the Allocation Advisory Board for the Follicular Lymphoma Foundation, the Advisory Committee for the IBD Ventures program for the Crohn’s & Colitis Foundation, and is an Expert Advisor for The Research Acceleration and Innovation Network (TRAIN) of the Milken Institute’s FasterCures division.